Gilead Sciences Business Segments — General and administrative expenses decreased by 23.0% to $553.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.5%, from $505.00M to $553.00M. Over 3 years (FY 2022 to FY 2025), Business Segments — General and administrative expenses shows relatively stable performance with a -1.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A decrease often signals successful operational streamlining or cost-saving initiatives, whereas an increase may reflect rising corporate overhead or investments in infrastructure.
This metric captures the overhead costs associated with the day-to-day operations of the business that are not directly...
Comparable to administrative overhead and corporate support costs reported by peer biopharmaceutical companies.
gild_segment_reportable_segment_general_and_administrative_expenses| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $585.50M | $585.50M | $585.50M | $585.50M | $704.50M | $704.50M | $704.50M | $704.50M | $632.00M | $572.00M | $584.00M | $850.00M | $505.00M | $501.00M | $527.00M | $718.00M | $553.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +20.3% | +0.0% | +0.0% | +0.0% | -10.3% | -9.5% | +2.1% | +45.5% | -40.6% | -0.8% | +5.2% | +36.2% | -23.0% |
| YoY Change | — | — | — | — | +20.3% | +20.3% | +20.3% | +20.3% | -10.3% | -18.8% | -17.1% | +20.7% | -20.1% | -12.4% | -9.8% | -15.5% | +9.5% |